Ulcerative Colitis

A new biochip, IBDchip, (Inflammatory Bowel Disease DNA Chip) is a pioneering programme which has the aim to have a direct influence in the quality of life of patients.

This chip has been created by the biotechnology enterprise Progenika Biopharma, and IDIBAPS-Hospital Cl?

c de Barcelona has led the multicentre study which demonstrates the improving of the prognosis and therapeutics applied to patients with inflammatory bowel disease.

Dr.

Miquel Sans, from the Gastroenterology Department of Hospital Cl?

c and collaborator of the IDIBAPS group Carlos Cara, of UCB Pharma, in the development of the diagnostic chip.

This study had the participation of 579 patients (335 of which with Crohn's disease and 344 with ulcerous colitis), and of the Central University Hospital of Asturias, University Clinical Hospital of Santiago de Compostela and Lozano Blesa Clinical Hospital of Zaragoza.

IBDchip includes the 61 polymorphisms that the scientific literature has until now associated to the inflammatory intestinal disease, the predisposition to suffer from it and its possible evolution.

This is an open tool that can be updated while new related mutations are identi...

Read more...